読み込み中
Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL), impacting both adult and pediatric demographics. A flagship offering is VDPHL01, an orally administered, non-hormonal medication specifically for chronic hair loss management in both male and female patients with PHL. Furthermore, Veradermics is progressing with VDMN, an innovative dissolvable microarray patch technology employing immunotherapy for common warts. Its research also extends to VDAA for addressing alopecia areata, and VDMC, aimed at molluscum contagiosum. Collectively, the firm's product candidates target conditions such as androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. Veradermics caters to healthcare practitioners and clinicians specializing in dermatologic and aesthetic care for patients of all ages, in addition to the wider medical and scientific community engaged in dermatology. Founded in 2019, the company is based in New Haven, Connecticut.
前日終値
$130.9
+$4.27 · +3.37%
時間外
$132.15
+$1.25 · +0.95%
10月9日 19:14 ET
日中の時刻はETです。市場データは遅延する場合があります。
Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL), impacting both adult and pediatric demographics. A flagship offering is VDPHL01, an orally administered, non-hormonal medication specifically for chronic hair loss management in both male and female patients with PHL. Furthermore, Veradermics is progressing with VDMN, an innovative dissolvable microarray patch technology employing immunotherapy for common warts. Its research also extends to VDAA for addressing alopecia areata, and VDMC, aimed at molluscum contagiosum. Collectively, the firm's product candidates target conditions such as androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. Veradermics caters to healthcare practitioners and clinicians specializing in dermatologic and aesthetic care for patients of all ages, in addition to the wider medical and scientific community engaged in dermatology. Founded in 2019, the company is based in New Haven, Connecticut.
日中レンジ
現在 $130.9
52週レンジ
現在 $130.9
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
40
割高
センチメント
58
まちまち
リスク
41
やや高いリスク
モメンタム
70
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL), impacting both adult and pediatric demographics. A flagship offering is VDPHL01, an orally administered, non-hormonal medication specifically for chronic hair loss management in both male and female patients with PHL. Furthermore, Veradermics is progressing with VDMN, an innovative dissolvable microarray patch technology employing immunotherapy for common warts. Its research also extends to VDAA for addressing alopecia areata, and VDMC, aimed at molluscum contagiosum. Collectively, the firm's product candidates target conditions such as androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. Veradermics caters to healthcare practitioners and clinicians specializing in dermatologic and aesthetic care for patients of all ages, in addition to the wider medical and scientific community engaged in dermatology. Founded in 2019, the company is based in New Haven, Connecticut.
日中レンジ
現在 $130.9
52週レンジ
現在 $130.9
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 |
|---|---|---|---|
| 研究開発 | 6206.5万 USD | 2328.3万 USD | 1497.1万 USD |
| 販売・一般管理 | 1028.2万 USD | 349.5万 USD | 235.3万 USD |
| 営業費用 | 7234.7万 USD | 2677.8万 USD | 1732.4万 USD |
| 受取利息 | 156.2万 USD | 48.1万 USD | 87万 USD |
| 支払利息 | — | 58.5万 USD | 3.6万 USD |
| 営業利益 | −7234.7万 USD | −2677.8万 USD | −1732.4万 USD |
| 純利益 | −6999.5万 USD | −2648.8万 USD | −1649万 USD |
会社概要が更新されました 2026年10月10日.
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$162.67
上昇余地（24.27%）評価サンプルは4件と限定的です
この株式へのエクスポージャーを報告している上場投資信託です。
iShares Russell 2000 ETFIWM7343.97万0.09%782.66億 USD0.19%$278.94+0.49%
Vanguard Morningstar Total Stock Market ETFVTI6100.28万0.00%2.3兆 USD0.03%$381.94+0.63%
Vanguard Extended Market ETFVXF2294.03万0.02%954億 USD0.05%$235+0.80%
Schwab U.S. Small-Cap ETFSCHA2099.73万0.10%217.28億 USD0.03%$32.79+0.40%
JPMorgan Active Growth ETFJGRO2091.74万0.21%102.21億 USD0.44%$98.31+0.92%
iShares Russell 2000 Growth ETFIWO1778.72万0.13%139.72億 USD0.24%$356.78+0.94%
iShares U.S. Pharmaceuticals ETFIHE1381.14万0.90%15.24億 USD0.37%$100.09+1.24%
Vanguard Russell 2000 ETFVTWO1231.04万0.07%180億 USD0.06%$112.66+0.50%iShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFSchwab U.S. Small-Cap ETFSCHAJPMorgan Active Growth ETFJGROiShares Russell 2000 Growth ETFIWOiShares U.S. Pharmaceuticals ETFIHEVanguard Russell 2000 ETFVTWOAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
